covi-vac (u.s. covid-19 vaccine) covi-vac (u.s. covid-19 vaccine) covi-vac (codenamed cdx-005) is a covid-19 vaccine developed by codagenix, inc. in december 2020, covi-vac started a phase i clinical trial, involving 48 participants. the trial was scheduled to complete in june 2021, with results to be reported by may 2022. on september 29, 2021, codagenix presented positive phase 1 data for covi-vac at idweek2021. data indicates that covi-vac is well tolerated, with no significant adverse events reported and that administration of the intranasal vaccine was immunogenic and capable of blocking nasal replication of the virus with minimal viral shedding, recorded at levels lower than those likely to result in subsequent transmission of covid-19. furthermore, covi-vac was shown to stimulate both serum and mucosal antibody immune responses. this article is about covid-19 vaccine developed by codagenix, inc.. for other uses, see covivac (disambiguation). covi-vac (u.s. covid-19 vaccine)vaccine descriptiontargetsars-cov-2vaccine typeattenuatedclinical datatrade namescdx-005other namescovi-vaxroutes ofadministrationintranasal part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal medical uses the vaccine is administered intranasally and requires a single dose. pharmacology covi-vac is a live attenuated vaccine. clinical trials phase i in december 2020, codagenix started a phase i trial in the united kingdom. in september 2021, codagenix reported that the trial had shown covi-vac to be safe and immunogenic.